Versant Ventures Raises $950 Million Across Three Vehicles $140 million companion fund to boost selected early high-performers $250 million opportunity fund for later-stage rounds
Versant Ventures today announced $950 million in additional capital allocated across a platform of three separate vehicles. These included Versant Venture Capital VIII, a $560 million primary global biotech fund; Versant Voyageurs II, a $140 million booster fund; and Versant Vantage II, a $250 million later-stage opportunity fund.
All three funds exceeded their initial targets and were heavily oversubscribed. The capital from existing investors and a select number of new top-tier limited partners will support Versant s highly successful biotech investment strategy and portfolio construction model.
Montreal’s Ventus Therapeutics raises $100-million to pursue ‘Holy Grail’ disease targets Bookmark Please log in to listen to this story. Also available in French and Mandarin. Log In Create Free Account
Getting audio file . This translation has been automatically generated and has not been verified for accuracy. Full Disclaimer
Marc Bruxelle/iStock Editorial / Getty Images
Ventus Therapeutics Inc. is the latest in a string of Canadian biotechnology startups to land significant funds from top North American investors.
The two-year-old Montreal company has raised US$100-million led by Boston-based RA Capital Management and backed by U.S. funds BVF Partners, Casdin Capital and Cormorant Asset Management, plus Fonds de solidarité FTQ, Canada’s leading institutional investor in the sector.